Both experts in the field, one with an academic view and one from industry, they discuss what can be done today with protein design, new innovations coming in the next year or two, and how they think about improving selectivity and sensitivity. Plus, how AI is changing the field, what it takes to be differentiated, and implications of new startups sharing less knowledge than has been traditionally done.

Servier's 'Golden Ticket' gave Deck Bio a place to work from at LabCentral and access to Servier's experts for advice. Jack and Irene discuss the benefits of this kind of support to a smaller company, and other ways more established players nurture the biotech ecosystem in hubs like Kendall Square.

In a wide-ranging discussion, Dr. Singh and Dr. Andtbacka reflect on the success of the immunotherapy field and the cancer centers that helped develop the new medicines, career leaps to industry, dealing with the risks of biotech, talking to investors, and advice for other CMOs.

Yossef Baidi and Fang Xie describe how getting involved in the club has benefited them, and the idea behind their new podcast (George Church and Peter Kolchinsky have already been guests). Plus, the September 19th career fair that traditionally draws 1,000 attendees and so far already has 17 companies participating this year.

She discusses the report and specifics on NIH funding, VC investment, jobs, biotech clusters within Massachusetts, and more.

They explain the size and depth of the cuts, and how it will affect research on both respiratory and non-respiratory conditions. Plus, what it means for global competitiveness for the United States going forward.

Lisa and Richard describe the unmet need for frontotemporal dementia and their partnership on AVB-101, which is administered directly to the thalamus. They describe the unique perspectives and skill sets that larger and smaller companies bring to the table in these types of partnerships, and discuss their thoughts on making it through times of change for the benefit of patients.

Interviewed by fellow veteran Jim Barsoum, Dr. Krieg shares multi-decade learnings from his previous companies Coley Pharmaceutical Group and Checkmate Pharmaceuticals, and describes how Zola builds off of that. He explains the importance of combining agonists to TLR9 to TLR7 and TLR8, and also describes the virtual set-up that the company has today.

Interviewed by Andy Plump, President of R&D at Takeda, Dr. Zerhouni discusses the rationale for multispecifics and the science behind them. They also discuss the differences between pharma and biotech, keys to being an effective R&D leader, and advice for both young and experienced people in their careers.

They discuss the difference between how biotech companies operate from large pharmas, including how history shows some new biotech innovations faced initial development and market pushback, and how good communication typically played a key role in why some overcame hurdles vs others. Plus, a description of Candel's viral immunotherapy approach.

Note: IDEA Pharma and Candel have a business relationship (as discussed).